Literature DB >> 19116567

Three tenets for staged correction of Kleeblattschädel or cloverleaf skull deformity.

Reza Jarrahy1, Henry K Kawamoto, Jennifer Keagle, Brian P Dickinson, Hurig V Katchikian, James P Bradley.   

Abstract

BACKGROUND: Patients with cloverleaf skull deformity are known to have high morbidity and poor outcome. Physical anomalies include a misshapen, trilobar skull, with a high "bossed" forehead, a bulging temporal region, and a flat posterior skull from multiple cranial suture fusion.
METHODS: Patients with cloverleaf skull deformity treated at the University of California, Los Angeles from 1990 to 2006 (n = 14) underwent early cranial vault remodeling (group 1) or staged correction with ventriculoperitoneal shunt (neonate), fronto-orbital advancement (3 to 6 months), and posterior vault remodeling (1 year) (group 2). Morbidity, necessary revisions, and neurologic (developmental testing) and aesthetic (Whitaker score) outcomes were assessed at follow-up.
RESULTS: Diagnoses included Apert syndrome, Crouzon syndrome, Pfeiffer syndrome, Saethre-Chotzen syndrome, and nonsyndromic. Early cranial vault remodeling patients had more complications than staged correction patients [pneumonia, meningitis, and excessive bleeding (each 66 percent versus 9 percent); wound infection (66 percent versus 18 percent); and seizure (100 percent versus 0 percent)]. Early cranial vault remodeling patients had prolonged intensive care unit and hospital stays compared with staged correction patients (13 versus 2 days and 27 versus 5 days, respectively). The Whitaker score showed acceptable results at 18 months in group 2 (1.4, no revisions necessary) but not in group 1 (2.8, minor to major bony recontouring). Developmental tests showed that all early cranial vault remodeling patients had lower scores in both preschool tests and global evaluations compared with normative data (mean preschool receptive scores, 95 versus 85; mean preschool expressive scores, 94 versus 87).
CONCLUSION: Staged correction of cloverleaf skull provided acceptable neurologic and aesthetic outcomes in the authors' series of patients.

Entities:  

Mesh:

Year:  2009        PMID: 19116567     DOI: 10.1097/PRS.0b013e3181934773

Source DB:  PubMed          Journal:  Plast Reconstr Surg        ISSN: 0032-1052            Impact factor:   4.730


  7 in total

Review 1.  Kleeblattschädel skull: a review of its history, diagnosis, associations, and treatment.

Authors:  R Shane Tubbs; Amit Sharma; Christoph Griessenauer; Marios Loukas; Mohammadali M Shoja; Koichi Watanabe; W Jerry Oakes
Journal:  Childs Nerv Syst       Date:  2012-12-12       Impact factor: 1.475

2.  Cloverleaf skull deformity and hydrocephalus.

Authors:  Guilherme Machado; Federico Di Rocco; Christian Sainte-Rose; Philippe Meyer; Daniel Marchac; Gaëlle Macquet-Nouvion; Eric Arnaud; Dominique Renier
Journal:  Childs Nerv Syst       Date:  2011-09-17       Impact factor: 1.475

Review 3.  Nervous system involvement in Pfeiffer syndrome.

Authors:  Ioannis N Mavridis; Desiderio Rodrigues
Journal:  Childs Nerv Syst       Date:  2020-10-20       Impact factor: 1.475

4.  Advances in the Treatment of Syndromic Midface Hypoplasia Using Monobloc and Facial Bipartition Distraction Osteogenesis.

Authors:  Anand R Kumar; Derek Steinbacher
Journal:  Semin Plast Surg       Date:  2014-11       Impact factor: 2.314

Review 5.  Syndromic Craniosynostosis: Complexities of Clinical Care.

Authors:  Justine O'Hara; Federica Ruggiero; Louise Wilson; Greg James; Graeme Glass; Owase Jeelani; Juling Ong; Richard Bowman; Michelle Wyatt; Robert Evans; Martin Samuels; Richard Hayward; David J Dunaway
Journal:  Mol Syndromol       Date:  2019-01-16

6.  Single-stage Total Cranial Vault Remodeling for Correction of Turricephaly: Description of a New Technique.

Authors:  Stephen Alex Rottgers; Ingrid Ganske; Isabelle Citron; Mark Proctor; John G Meara
Journal:  Plast Reconstr Surg Glob Open       Date:  2018-08-08

7.  Kleeblattschädel in Pfeiffer syndrome type II.

Authors:  Cory M Pfeifer
Journal:  Radiol Case Rep       Date:  2020-02-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.